This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea

This study has been completed.
Natal Bioproducts Institute
Information provided by (Responsible Party):
Jo M Wilmshurst, University of Cape Town Identifier:
First received: February 1, 2008
Last updated: December 3, 2014
Last verified: December 2014
Children are at risk of developing an involuntary movement disorder after streptococcal throat infections. Not all children are affected and the severity is individually variable. Affected children have alteration in their behaviour and mood and can become quite compromised in their activities of daily living. The condition is believed to be related to the body having an over efficient immune response to the infection and some of the antibodies made in response to the infection also "attack" centres in the brain controlling movement and mood. Treating these children with immunoglobulins, which "mop up" the antibodies may reverse or improve affected children. This study hopes to clarify this.

Condition Intervention
Sydenham Chorea Post Streptococcal Movement Disorder Biological: Intravenous immunoglobulin Drug: standard interventions penicillin VK and haloperidol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea

Resource links provided by NLM:

Further study details as provided by Jo M Wilmshurst, University of Cape Town:

Primary Outcome Measures:
  • improved scores on the sydenham chorea assessment charts [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • improved quality of life [ Time Frame: 2 years ]

Enrollment: 20
Study Start Date: May 2002
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
Biological: Intravenous immunoglobulin
intravenous immunoglobulin 2g/kg total given over 2 days
Placebo Comparator: 2
Group randomized to receive standard intervention for sydenham's chorea alone
Drug: standard interventions penicillin VK and haloperidol
Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day

  Show Detailed Description


Ages Eligible for Study:   4 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Sydenham chorea moderate to severe (affecting activities of daily living) Raised ASOT titre

Exclusion Criteria:

  • Mild Sydenham chorea (not affecting activities of daily living)
  • Exclusion of systemic lupus erythematosus
  • Exclusion of Wilson's disease
  • Exclusion of toxin ingestion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00615797

South Africa
Red Cross Children's Hospital
Cape Town, Western Cape, South Africa, 7700
Sponsors and Collaborators
University of Cape Town
Natal Bioproducts Institute
Principal Investigator: Kathleen Walker, MB ChB Red Cross Children's Hospital, University of Cape Town
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jo M Wilmshurst, Prof, University of Cape Town Identifier: NCT00615797     History of Changes
Other Study ID Numbers: CTXO1-2002
Study First Received: February 1, 2008
Last Updated: December 3, 2014

Additional relevant MeSH terms:
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Haloperidol decanoate
Penicillin V
Immunologic Factors
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017